ArticleClinical and vaccine immunology : CVI2012
A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.
Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 63 citations in OpenAlex.
- Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.Human vaccines & immunotherapeutics · 2015Trial
- Rational Combination of Dominant and Subdominant Antigens with Nanoadjuvant Elicits Durable Immunity AgainstVaccines · 2026Article
- Dual-mode ClfA-targeting DARPin biologics protect against diverse methicillin-resistantbioRxiv : the preprint server for biology · 2026Article
- Article
- Eicosapentaenoic Acid and Docosahexaenoic Acid as an Antimicrobial Agent in Orthopedics-An In Vitro Study About the Race for Surface.Pathogens (Basel, Switzerland) · 2025Article
- Article
- Bacteria in Fluid Flow.Journal of bacteriology · 2023Review
- Review
- Differential binding of human and murine IgGs to catalytic and cell wall binding domains of Staphylococcus aureus peptidoglycan hydrolases.Scientific reports · 2021Article
- Performance of a Four-AntigenMicroorganisms · 2021Article
- Multi-Antigen Outer Membrane Vesicle Engineering to Develop Polyvalent Vaccines: TheFrontiers in immunology · 2021Article
- Dissecting the Human Response toFrontiers in immunology · 2021Article
- Evaluation of the Efficacy of a Cholera-Toxin-BasedVaccines · 2020Article
- Harnessing antifungal immunity in pursuit of a Staphylococcus aureus vaccine strategy.PLoS pathogens · 2020Article
- Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a NovelOpen forum infectious diseases · 2020Article
- Molecular epidemiology and expression of capsular polysaccharides in Staphylococcus aureus clinical isolates in the United States.PloS one · 2019Article
- The development of a staphylococcus aureus four antigen vaccine for use prior to elective orthopedic surgery.Human vaccines & immunotherapeutics · 2019Review
- Two Vaccines formSphere · 2018Article
- Human antibody responses against non-covalently cell wall-bound Staphylococcus aureus proteins.Scientific reports · 2018Article
- Safety, tolerability, and immunogenicity of a novel 4-antigenHuman vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus is a Gram-positive pathogen that causes devastating disease and whose pathogenesis is dependent on interactions with host cell factors. Staphylococcal clumping factor A (ClfA) is a highly conserved fibrinogen (Fg)-binding protein and virulence factor that contributes to host tissue adhesion and initiation of infection. ClfA is being investigated as a possible component of a staphylococcal vaccine. We report the development of an Fg-binding assay that is specific for ClfA-mediated binding. Using the assay, we show that despite the presence of anti-ClfA antibodies, human sera from unvaccinated subjects are unable to prevent the binding of S. aureus to an Fg-coated surface. In contrast, antibodies elicited by a recombinant ClfA-containing vaccine were capable of blocking the ClfA-dependent binding of a diverse and clinically relevant collection of staphylococcal strains to Fg. These functional antibodies were also able to displace S. aureus already bound to Fg, suggesting that the ligand-binding activity of ClfA can be effectively neutralized through vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.